Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Indeterminate Lesions: later-stage trial registry

1 of 1 indexed Indeterminate Lesions trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Indeterminate Lesions: 1 US clinical trial tracked, 1 recruiting.

Indeterminate Lesions is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Aura Biosciences, running 1 of these trials.

Enrollment posture brief

Registry condition indeterminate-lesions

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Indeterminate Lesions (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Indeterminate Lesions

Indeterminate Lesions lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Indeterminate Lesions on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Indeterminate Lesions is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Aura Biosciences 1 trials

Named interventions

Most-linked intervention names on Indeterminate Lesions records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sham Microinjector Device
1 trials
Sham Infrared Laser Device
1 trials
Infrared Laser Device
1 trials
Suprachoroidal Microinjector Device
1 trials
Bel-sar Drug
1 trials

US sites by state

Facility locations filed on Indeterminate Lesions trials. A trial with sites in several states counts in each.

Oklahoma 1 trials
Ohio 1 trials
New York 1 trials
Nebraska 1 trials
North Carolina 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Indeterminate Lesions page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Indeterminate Lesions trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Aura Biosciences sponsors the most Indeterminate Lesions trials on record, review their full trial history before evaluating a specific study. See Aura Biosciences's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Indeterminate Lesions condition card totals 1 registered trials; most-linked intervention Sham Microinjector; top US site state Oklahoma. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.